Despite recent advances in transgenic animal models and display technologies,
humanization of mouse sequences remains one of the main routes for therapeutic antibody …

Monoclonal antibodies play an increasingly important role for the development of new drugs
across multiple therapy areas. The term ‘developability’ encompasses the feasibility of …

Programmed death ligand 1 (PD-L1) is an immune regulatory ligand that binds to the T-cell
immune check point programmed death 1. Tumor expression of PD-L1 is correlated with …

Introduction Anterior-gradient 2 (AGR2) is an estrogen-responsive secreted protein. Its
upregulation has been well documented in a number of cancers, particularly breast cancer, for …

Identification of favorable biophysical properties for protein therapeutics as part of
developability assessment is a crucial part of the preclinical development process. Successful …

Glucocorticoids (GCs) are excellent anti-inflammatory drugs but are dose-limited by on-target
toxicity. We sought to solve this problem by delivering GCs to immune cells with antibody–…

Interleukin-17A (IL-17A) is a pro-inflammatory cytokine secreted by a subset of memory T
cells and other innate immune cells. It is associated with rheumatoid arthritis (RA) due to IL-…

ABSTRACT Characterization of charge heterogeneity in monoclonal antibodies (mAbs) is
needed during developability assessment and downstream development of drug candidates. …

Background Immune checkpoint inhibitors (ICI) have radically changed cancer therapy, but
most patients with cancer are unresponsive or relapse after treatment. MK-5890 is a CD27 …

Production of site-specific cysteine-engineered antibody-drug conjugates (ADCs) in mammalian
cells may produce developability challenges, fragments, and heterogenous molecules, …